Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, and La Trobe University, Heidelberg, Australia; Department of Surgery, University of Melbourne, Melbourne, Australia; School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
PET Clin. 2024 Apr;19(2):231-248. doi: 10.1016/j.cpet.2023.12.009. Epub 2024 Jan 16.
Skin cancers are the most common cancers, with melanoma resulting in the highest cause of death in this category. Accurate clinical, histologic, and imaging staging with fludeoxyglucose positron emission tomography (FDG PET) is most important to guide patient management. Whilst surgical excision with clear margins is the gold-standard treatment for primary cutaneous melanoma, targeted therapies have generated remarkable and rapid clinical responses in melanoma, for which FDG PET also plays an important role in assessment of treatment response and post-therapy surveillance. Non-FDG PET tracers, advanced PET technology, and PET radiomics may potentially change the landscape of the utilization of PET in the imaging of patients with cutaneous malignancies.
皮肤癌是最常见的癌症，黑色素瘤是此类癌症中导致死亡的主要原因。通过氟脱氧葡萄糖正电子发射断层扫描（FDG PET）进行准确的临床、组织学和影像学分期对于指导患者管理至关重要。虽然手术切除加清晰切缘是原发性皮肤黑色素瘤的金标准治疗方法，但靶向治疗已在黑色素瘤中产生了显著而快速的临床反应，FDG PET 在评估治疗反应和治疗后监测方面也发挥着重要作用。非 FDG PET 示踪剂、先进的 PET 技术和 PET 放射组学可能会改变 PET 在皮肤恶性肿瘤患者成像中的应用前景。
